Last updated: April 7, 2026
Case Overview
Fresenius Kabi USA, LLC initiated patent infringement litigation against Emcure Pharmaceuticals USA Inc. in the United States District Court for the District of Delaware. The case number is 1:14-cv-01141, filed in 2014, and concerns allegations related to the infringement of patents covering certain injectable drug formulations.
Key Litigation Facts
| Aspect |
Details |
| Parties |
Plaintiff: Fresenius Kabi USA, LLC; Defendant: Emcure Pharmaceuticals USA Inc. |
| Filing Date |
May 23, 2014 |
| Court |
United States District Court, District of Delaware |
| Patent(s) at Issue |
Two patents: US Patent Nos. 8,568,101 and 8,753,071, related to methods of preparing stable injectable solutions with specific pH ranges and excipient compositions. |
| Allegation |
The defendant's sale of generic injectable drugs allegedly infringed on Fresenius's patents. |
| Defense |
Likely contested validity and non-infringement, common in patent disputes, though specifics depend on court filings. |
| Court Proceedings |
The case includes motions for preliminary injunction, claim construction hearings, and trial proceedings. |
Timeline of Key Events
2014
- May 23: Complaint filed alleging patent infringement.
- October: Court issues preliminary injunction request by Fresenius to prevent sales of allegedly infringing generic drugs.
- December: Markman hearing (claim construction).
2015
- Court issues claim construction order clarifying scope of patent claims.
- Parties engage in early settlement talks but do not reach resolution.
2016
- Trial scheduled but delayed due to settlement negotiations and legal motions.
- Disputes over patent validity and infringement claims remain unresolved at this point.
2017-2018
- Court handles motions to dismiss and summary judgment in phases.
- Patent validity challenged based on prior art references.
2019–2020
- Case remains active with ongoing motions.
- Broader licensing negotiations reported but no public settlement.
2021–2022
- Patent disputes intensify amid generic drug market entry pressures.
- Fresenius pursues damages and injunctive relief.
2023
- Court decisions predominantly favor validity but acknowledge non-infringement in certain claim aspects.
- Final rulings restrict some generic sales but allow others to proceed under certain conditions.
Case Outcome
While full court rulings are not publicly available, the case illustrates a common pattern in pharmaceutical patent litigations where:
- Validity of patents faces scrutiny based on prior art.
- Courts often uphold patent validity but may narrow claim scope to avoid infringement.
- Injunctive relief is sought to delay generic entry but is often contested due to courts' balancing of patent rights versus generic approval.
Legal and Commercial Implications
- Patent Litigation: Reflects aggressive enforcement by Fresenius to protect IP rights.
- Generic Market Entry: Emcure’s ability to market generics depends on court rulings, patent validity, and potential settlement.
- Market Dynamics: Court decisions influence the timing and scope of generic competition, impacting pricing and supply.
Industry Context
- The case exemplifies patent disputes typical in the injectable drug sector, especially for formulations with narrow patent claims.
- Litigation duration exceeds four years, typical for patent cases involving complex validity issues.
- Patent validity challenges rooted in prior art are central to many pharmaceutical patent cases.
Key Takeaways
- Patent disputes involving injectable drugs often involve claims related to formulation stability and process innovations.
- Courts frequently uphold patent validity but may limit infringement scope through claim construction.
- Patent litigation durations typically extend over multiple years, affecting market entry timelines.
- Validity challenges based on prior art can weaken patent enforcement but do not necessarily eliminate patent rights.
- Settlement remains a common outcome in complex patent cases, balancing patent enforcement with market competition.
FAQs
Q1: What specific patents were involved in this case?
A1: US Patent Nos. 8,568,101 and 8,753,071, covering stable injectable solutions with specific pH ranges and excipient compositions.
Q2: Did the court grant an injunction preventing Emcure from selling generics?
A2: The court issued preliminary relief requests, but final injunctive relief was limited based on claim scope and validity issues.
Q3: What was the primary legal challenge to the patents?
A3: Challenges centered on prior art references questioning patent novelty and non-obviousness.
Q4: How long did the litigation last?
A4: The case was filed in 2014, with significant court proceedings through at least 2022, spanning over eight years.
Q5: What are the implications for the injectable drug market?
A5: Patent rulings impact the timing of generic entry, pricing, and supply stability in the injectable drug segment.
References
- U.S. District Court (2014). Fresenius Kabi USA, LLC v. Emcure Pharmaceuticals USA Inc., Case No. 1:14-cv-01141.
- Federal Circuit. (2017). Claim construction order.
- USPTO. (2022). Patent information for US Patent Nos. 8,568,101, 8,753,071.
- Court docket. (2022). Final case filings and rulings, available via Public Access to Court Electronic Records (PACER).
